In recent years, medications like Ozempic, Wegovy, and Mounjaro have revolutionized the treatment of obesity and type 2 diabetes, becoming a cultural phenomenon that has transcended doctors' offices. These drugs, known as GLP-1 receptor agonists, mimic a gut hormone that regulates appetite and blood sugar, achieving significant weight loss that previously seemed unattainable without surgery. Celebrities, influencers, and millions of people around the world have turned to these weekly injections, fueling unprecedented demand that has led to shortages in some markets and debates about their use beyond medical indications. However, as more people begin these treatments, an inevitable question arises: what happens when they stop using them? The promise of an effective weight-loss solution has led many to start treatment without fully understanding that these medications were designed for long-term, potentially lifelong, use. Research and patient experiences are revealing a complex reality: discontinuing injections can trigger a series of physical and metabolic changes that challenge the expectation of maintaining the results achieved.

Pros and Cons of GLP-1 Agonists

The effectiveness of GLP-1 medications for weight loss is undeniable. Clinical studies have shown that patients treated with semaglutide (the active ingredient in Ozempic and Wegovy) can lose between 15% and 20% of their body weight, while tirzepatide (Mounjaro) has shown even more impressive results, with losses exceeding 20% ??in some cases. These numbers represent a monumental advance in medicine, comparable to the results of some bariatric surgeries but without going under the knife.

However, the scientific evidence is compelling regarding what happens after treatment is discontinued.

Research published in prestigious medical journals has documented that most patients regain a significant portion of the weight lost within a year of stopping the medication. A study conducted on semaglutide revealed that participants regained approximately two-thirds of the weight lost within 12 months of discontinuing treatment. Discontinuation of Medication: The mechanism behind this weight regain is multifaceted. These medications work by reducing appetite, slowing gastric emptying, and increasing the feeling of satiety. When discontinued, these effects gradually disappear. The body, which experienced sustained calorie reduction during treatment, may respond by increasing hunger signals as a compensatory mechanism. Some patients report feeling a more intense appetite than before starting treatment, although experts debate whether this represents a hormonal rebound or simply a return to the previous state. Beyond weight, discontinuing these medications can have other metabolic consequences. For people with type 2 diabetes, stopping treatment often results in a deterioration of glycemic control, with glycated hemoglobin levels rising again. The cardiovascular benefits observed during treatment, such as reduced blood pressure and improvements in lipid profiles, also tend to gradually reverse. The psychological aspect of discontinuing treatment should not be underestimated. Many patients experience frustration, anxiety, or a sense of failure as they see their weight return. There is also a risk of developing a problematic relationship with food or with the medication itself, especially if treatment was started without adequate accompanying lifestyle changes. Obesity and endocrinology specialists emphasize that these medications are not a cure, but rather a chronic treatment for a chronic condition. Obesity is recognized by medical organizations as a complex disease with genetic, metabolic, environmental, and behavioral components. From this perspective, expecting to maintain weight loss after discontinuing the medication would be comparable to expecting blood pressure to remain controlled after stopping antihypertensive drugs. However, not all patients experience complete weight regain. Those who manage to implement substantial changes in their diet, physical activity, and lifestyle habits during treatment have a better chance of maintaining at least some of the results. Support from nutritionists,Psychologists specializing in eating behavior and structured exercise programs can make a significant difference.

The era of GLP-1 medications is just beginning, and with it comes the need to rethink how society and medicine understand and address obesity: not as a matter of willpower, but as a complex medical condition that, like so many others, may require sustained treatment for effective management.

You may also be interested in: